Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
338 Views
Emedinexus 06 May 2024
IntroductionRituximab is an effective and safe treatment for pediatric patients with frequently relapsing or steroid-dependent nephrotic syndrome (FR/SDNS). AimThe present study analyzed the efficacy and safety of Rituximab in adult FR/SDNS patients with minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS).Methods:This retrospective study examined relapse frequency and first relapse-free survival time. It also recorded adverse events. Results:The study prescribed an average rituximab dose of 1,393.8 ± 618.7 mg/2 years to 81 patients during the 2-year follow-up period. It observed a significant decrease in relapse frequency after rituximab treatment. The first relapse-free survival time was 16.7 ± 8.0 months. 70.4% achieved cessation of corticosteroids and immunosuppressants within three months following the first rituximab infusion.Adverse events were mostly mild, and no severe treatment-related adverse events occurred. Low serum albumin levels before Rituximab and high CD56+CD16+ natural killer cell count remained independent risk factors of relapse within two years after Rituximab treatment.ConclusionThis study proves Rituximab is an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.
Reference-
Lan L, Lin Y, Yu B, et al. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study. Am J Nephrol. 2024;55 (1): 25–36.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}